BioForm Medical, Inc. (BFRM) financial news, and detailed stock charts
This company symbol is outdated. Results displayed are archieved for your information
BioForm Medical, Inc. (BFRM) Stock Summary:
Our Business We are a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient’s appearance. Our core product, RADIESSE® injectable dermal filler, is designed to provide long-lasting, cost-effective and safe aesthetic improvement for patients. Our clinical studies have demonstrated that RADIESSE® provides meaningful initial aesthetic correction and approximately 12 months’ duration of aesthetic improvement in many patients, resulting in high patient satisfaction. Physicians have used RADIESSE® for more than six years, and we have shipped over 800,000 syringes worldwide. Our strategy is to become a worldwide leader in medical aesthetics by building on our success with RADIESSE®, gaining a market leading position in dermal fillers, and commercializing new products beyond dermal fillers that enhance the practice of medical aesthetics. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f09%2f26%2f0001193125-08-201634.html#FIS_BUSINESS"Archieved Financial News About BioForm Medical, Inc.
Merz Pharma Group Successfully Completes Bioform Medical Tender Offer with over 94 Percent of Shares Tendered
2010-02-17 03:57:23
Quote: The tender offer expired at 12:00 midnight,Eastern Standard Time, on February 12, 2010.Based on final information from the depositary for the tender offer,44,706,581 shares (including 7,103,759 shares subject to guaranteeddelivery procedures), representing over 94 percent of the outstandingshares of common stock of BioForm Medical were validly tendered and notwithdrawn prior to the expiration of the tender offer. All such shareshave been accepted for payment in accordance with the terms of thete...Read article
BIOFORM MEDICAL INC Files SEC form 10-Q, Quarterly Report
2010-02-17 03:57:22
Quote: ("ACI") whereby we received approximately
$1.7 million, net of related expenses, from the escrow related to the April 2008
Asset Purchase Agreement between BioForm Medical, Inc. and ACI.
Pre-acquisition Costs
During the second quarter of fiscal 2010 we recognized pre-acquisition costs of
$1.5 million related to the tender offer by Merz Pharma Group to acquire all of
the outstanding stock of BioForm Medical, Inc.
Other Income (Expense), Net
Other income (expense), net for the second...Read article
Merz Obtains HSR Clearance in Connection with BioForm Medical Tender Offer
2010-02-03 02:24:43
Quote: The tender offer will expire on February 12, 2010 at 12:00midnight, New York City time, unless extended.Forward-Looking StatementsThis press release contains forward-looking statements, including thoserelating to Merz’s anticipated acquisition of BioForm Medical.Forward-looking statements may contain words such as “expect,â€â€œbelieve,†“may,†“can,†“should,†“will,†“forecast,†“anticipate†orsi...Read article
Finkelstein Thompson LLP Announces Investigation of BioForm Medical, Inc.
2010-01-26 02:29:20
Quote: Read article
Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of BioForm Medical, Inc.
2010-01-26 02:29:19
Quote: BFRMNews) related to theCompany’s merger agreement with Merz Pharma Group ("Merz") – a privatelyheld company based in Frankfurt, Germany – to acquire BioForm Medical ina cash transaction valued at approximately $253 million, based on theCompany’s outstanding shares of common stock.Under the terms of a definitive agreement entered into by the parties,Merz will acquire all of the outstanding shares of BioForm Medical for$5.45 per share in cash pursuant to a cash tender ...Read article
Bull & Lifshitz, LLP Announces Investigation of BioForm Medical, Inc.
2010-01-26 02:29:17
Quote: Press ReleaseSource: Bull & Lifshitz, LLPOn Tuesday January 12, 2010, 4:32 pm ESTNEW YORK--(BUSINESS WIRE)--Bull & Lifshitz, LLP announces an investigation into possible breachesof fiduciary duty and violations of state law in connection with theproposed sale of BioForm Medical, Inc. (Nasdaq: - You may contact Peter D. Bull, Esq. or Joshua M. Lifshitz, Esq. at 18East 41st Street, New York, NY, 10017, by telephone at: (866) 313-6222or by sending an e-mail including your contact information to...Read article
The Shuman Law Firm Announces Investigation on Behalf of BioForm Medical, Inc. Shareholders
2010-01-26 02:29:16
Quote: BFRMNews) related to the Company’s merger agreement withMerz Pharma Group ("Merz"), a privately held company based in Frankfurt,Germany.The cash transaction is valued at approximately $253 million, based onthe Company’s outstanding shares of common stock.Under the terms of a definitive agreement entered into by the parties,Merz will acquire all of the outstanding shares of BioForm Medical for$5.45 per share in cash pursuant to a cash tender offer followed by asecond-step merger. Fo...Read article
Merz Commences Tender Offer for All Outstanding Shares of BioForm Medical
2010-01-26 02:29:16
Quote: andBioForm Medical, announced on January 4, 2010, and pursuant to an Offerto Purchase dated January 15, 2010.The tender offer is scheduled to expire at 12:00 midnight, New York CityTime, on February 12, 2010, unless extended. Pursuant to the terms andsubject to the conditions of the merger agreement, following thecompletion of the tender offer, Vine Acquisition Corp. will merge withand into BioForm Medical, with BioForm Medical surviving the merger asan indirect wholly owned subsidiary of Merz. ...Read article
BioForm Medical Reports Financial Results for Quarter Ended December 31, 2009, Second Quarter of Fiscal 2010; Pipeline Update
2010-01-26 02:29:16
Quote: Operating expenses for the quarter ended December 31, 2009 also included a $1.7 million gain, net of legal and other expenses, from the ACI Escrow settlement, and approximately $1.5 million in expenses related to the Merz transaction.
Earnings per share for the quarter ended December 31, 2009 was $0.03 as compared to net loss per share of $0.17 for the quarter ended December 31, 2008.
As of December 31, 2009, BioForm Medical had $46.1 million in cash and cash equivalents, an increase of $3.2 m...Read article
BIOFORM MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
2010-01-19 04:47:29
Quote: Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1Press Release dated January 15, 2010.
Additional Information
In January 2010, a wholly-owned acquisition subsidiary of Merz Pharma Group
("Merz") will commence a tender offer to purchase all of the outstanding shares
of BioForm Medical common stock for US$5.45 per share, net to the seller in
cash, without interest and less any required tax withholding. The Board of
Directors of BioForm Medical has unanimously resolved to...Read article
BioForm Medical Reports Financial Results for Quarter Ended December 31, 2009, Second Quarter of Fiscal 2010; Pipeline Update
2010-01-19 04:47:29
Quote: Operating expenses for the quarter ended December 31, 2009 also included a $1.7 million gain, net of legal and other expenses, from the ACI Escrow settlement, and approximately $1.5 million in expenses related to the Merz transaction.
Earnings per share for the quarter ended December 31, 2009 was $0.03 as compared to net loss per share of $0.17 for the quarter ended December 31, 2008.
As of December 31, 2009, BioForm Medical had $46.1 million in cash and cash equivalents, an increase of $3.2 m...Read article
The Shuman Law Firm Announces Investigation on Behalf of BioForm Medical, Inc. Shareholders
2010-01-19 04:47:28
Quote: BFRMNews) related to the Company’s merger agreement withMerz Pharma Group ("Merz"), a privately held company based in Frankfurt,Germany.The cash transaction is valued at approximately $253 million, based onthe Company’s outstanding shares of common stock.Under the terms of a definitive agreement entered into by the parties,Merz will acquire all of the outstanding shares of BioForm Medical for$5.45 per share in cash pursuant to a cash tender offer followed by asecond-step merger. Fo...Read article
Merz Commences Tender Offer for All Outstanding Shares of BioForm Medical
2010-01-19 04:47:28
Quote: andBioForm Medical, announced on January 4, 2010, and pursuant to an Offerto Purchase dated January 15, 2010.The tender offer is scheduled to expire at 12:00 midnight, New York CityTime, on February 12, 2010, unless extended. Pursuant to the terms andsubject to the conditions of the merger agreement, following thecompletion of the tender offer, Vine Acquisition Corp. will merge withand into BioForm Medical, with BioForm Medical surviving the merger asan indirect wholly owned subsidiary of Merz. ...Read article
Bull & Lifshitz, LLP Announces Investigation of BioForm Medical, Inc.
2010-01-13 04:17:50
Quote: Press ReleaseSource: Bull & Lifshitz, LLPOn Tuesday January 12, 2010, 4:32 pm ESTNEW YORK--(BUSINESS WIRE)--Bull & Lifshitz, LLP announces an investigation into possible breachesof fiduciary duty and violations of state law in connection with theproposed sale of BioForm Medical, Inc. (Nasdaq: - You may contact Peter D. Bull, Esq. or Joshua M. Lifshitz, Esq. at 18East 41st Street, New York, NY, 10017, by telephone at: (866) 313-6222or by sending an e-mail including your contact information to...Read article
Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of BioForm Medical, Inc.
2010-01-07 01:36:09
Quote: BFRMNews) related to theCompany’s merger agreement with Merz Pharma Group ("Merz") – a privatelyheld company based in Frankfurt, Germany – to acquire BioForm Medical ina cash transaction valued at approximately $253 million, based on theCompany’s outstanding shares of common stock.Under the terms of a definitive agreement entered into by the parties,Merz will acquire all of the outstanding shares of BioForm Medical for$5.45 per share in cash pursuant to a cash tender ...Read article
Finkelstein Thompson LLP Announces Investigation of BioForm Medical, Inc.
2010-01-06 01:51:29
Quote: Read article
StockPreacher Initiates Independent Research Coverage for BioForm Medical Inc.
2010-01-06 01:51:29
Quote: The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.http://www.stockpreacher.com/n/BFRMhttp://twitter.com/StockPreacherBioForm Medical Inc. (BFRM) engages in the development and commercialization of products that are used by physicians to enhance a patient's appearance. The Company's lead product is RADIESSE(R) dermal filler, a long-lasting filler for use in facial aesthetics. Its cl...Read article
BioForm Medical being acquired by German firm
2010-01-05 03:14:51
Quote: BioForm Medical Inc., a San Mateo, Calif., biotech company that has a production facility in Franksville in Racine County, has agreed to be purchased by German pharmaceutical company Merz Pharma Group in a transaction valued at $253 million.Merz, based in Frankfurt am Main, Germany, will acquire all of the outstanding shares of BioForm Medical for $5.45 per share in cash under a cash tender offer followed by a second-step merger. The cash purchase price represents a premium of 55 percent more th...Read article
Kendall Law Group Investigates BioForm Medical, Inc. on Behalf of Shareholders
2010-01-05 03:14:49
Quote: Read article
Merz to acquire BioForm
2010-01-05 03:14:48
Quote: Merz Pharma Group will acquire BioForm Medical in a deal worth about $253 million, according to an announcement from the Frankfurt, Germany-based Merz.Merz bases its U.S. pharmaceutical operations at offices in Piedmont Center in High Point. BioForm is based in San Mateo, California.According to the announcement, BioForm produces the dermal filler product Radiesse. Once the acquisition closes, Merz will create a new Merz Aesthetics to be based in San Mateo to produce products used by plastic sur...Read article
You can still leave a comment about BioForm Medical, Inc. BFRM
Besides BioForm Medical, Inc.'s Stock there is more great Microcap and Stock Market information available at Realpennies.com